Souhaitez-vous accéder aux communiqués récents ?

PALM BEACH, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around...

Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Selective Estrogen Receptor Modulators Market by Product Type, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast to...

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published...

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of...

4D Path QPORTM platform delivers unprecedented predictive insights for patients with low immune infiltrates—achieving a 66% response rate

Using just 1mL of plasma, the Precede Bio platform identified key molecular pathways linked to response and resistance in patients with metastatic breast and prostate cancer treated with sacituzumab...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with...

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2025" has been added to ResearchAndMarkets.com's offering. The anti-cancer monoclonal antibodies (mAbs) market is...

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology...

New York, USA, April 30, 2025 (GLOBE NEWSWIRE) -- Metastatic HR+/HER2- Breast Cancer Market—The Road Ahead for Targeted Therapies and Personalized Medicine | DelveInsight  In recent years, the...